Bayer CropScience Ltd

Q4 FY19Fertilizers & Agrochemicals

Bayer CropScience Q4 FY19 earnings call: Revenue & Margins

Q4 FY19 investor presentation: what the company reported on revenue, margins and projects.

Price₹3,736

Market cap₹17.0K Cr

P/E23.2

Updated24 Sept 2026

Read4 min read

Based on Bayer CropScience Ltd's Q4 FY19 investor presentation. The company has not published an earnings-call transcript for this quarter, so figures here are what the presentation reports, not management guidance.

The short version

Q1 2019 Crop Science segment sales: €6,444 million, +5.5% year-on-year (YoY) currency- and portfolio-adjusted - Pharmaceuticals sales: €4,354 million, +5.3% YoY - Consumer Health sales: €1,395 mil EBITDA and operating margin figures for Q1 2019 are not explicitly stated in the provided pages of the investor presentation.

From Bayer CropScience Ltd's Q4 FY19 earnings-call transcript · updated 24 Sept 2026.

Revenue & Sales Performance

Q1 2019 Crop Science segment sales: €6,444 million, +5.5% year-on-year (YoY) currency- and portfolio-adjusted
Pharmaceuticals sales: €4,354 million, +5.3% YoY
Consumer Health sales: €1,395 million, –1.4% YoY
Animal Health sales: €421 million, –0.9% YoY
Crop Science EBITDA before special items grew +122.8% YoY
No explicit overall revenue or volume outlook stated in the presentation
Bayer CropScience Ltd FY 2018-19 total income: ₹27,229 million, slightly down from ₹27,878 million previous year

2 more points management made on revenue & sales performance

Profitability & Margins

EBITDA and operating margin figures for Q1 2019 are not explicitly stated in the provided pages of the investor presentation.
Sales for Crop Science segment in Q1 2019 stood at €6,444 million, with a year-on-year currency- and portfolio-adjusted growth of +5.5% (Page 8).
EBITDA before special items is also not explicitly provided in the extract.
Profit (PAT) figures for the quarter are not provided in the extracted content.

2 more points management made on profitability & margins

See what Bayer CropScience Ltd said on profitability & margins — free account, 30 seconds.

Capital Expenditure Plans

The investor presentation does not explicitly detail any specific capex amounts, capacity expansions, or new plant/projects with their costs, statuses, or timelines. The focus is primarily on: - Integration of Monsanto India Limited (MIL) with Bayer CropScience Limited (BCSL), with key merger milestones and approvals targeted around June-July 2019 and post Q3 CY 2019 activities (Page 15). - Expansion of genomic and data science capabilities for rice breeding 2019-2029 to improve yield, quality, and costs; includes expanding and modernizing field testing and building IT capabilities (Page 21). - Broad transformation priorities including advancing digital transformation and operational excellence (Page 29). No specific capital expenditure figures, new plant projects, or capacity expansion timelines are directly stated in the presentation.

Top-ranked in Fertilizers & Agrochemicals

Ranked on what management guided this quarter

5x potential

1Anya Polytech &₹211 Cr

Rev 2Mar 1

2Dharmaj Crop₹998 Cr

Rev 2Mar 2

3₹7.4K Cr

Rev 2Mar 3

4₹5.8K Cr

Rev 2Mar 3

5₹1.3K Cr

Rev 3Mar 1

Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.

Fundraising & Capital Structure

The investor presentation provided does not explicitly mention any fundraising activities through debt or equity, nor does it state any changes in borrowings or net debt. Key points related to financials include: - Balance Sheet Overview on page 28 showing assets, liabilities, and shareholders’ funds with percentage changes over the previous year but no mention of borrowings or debt changes. - Profitability and income overviews (pages 26-27) focus on revenue, expenses, and profit before tax without reference to fundraising or borrowings.

- The merger with Monsanto India Limited (MIL) and related integration activities are discussed, but no explicit details on debt or equity issuance are provided. - The presentation includes synergy and efficiency programs and operational targets without touching on capital raising through borrowings or equity. Therefore, based solely on this presentation, there is no disclosed information about fundraising via debt or equity or changes in borrowings/net debt.

2 more points management made on fundraising & capital structure

See what Bayer CropScience Ltd said on fundraising & capital structure — free account, 30 seconds.

Order Book & Pipeline

The investor presentation provided does not specifically report or mention details on order book, order inflow, or pending orders. The presentation primarily covers: - Business updates including financial performance, merger integration with Monsanto India Limited, and strategic priorities. - Financial figures like inventories, trade receivables, fixed assets, shareholders’ funds, trade payables, and liabilities. - Profitability overview and income breakdown.

2 more points management made on order book & pipeline

Bayer CropScience Ltd — Quarterly revenue & net profit

Revenue Net profit

Dec 2024

Mar 2025

Jun 2025

Sep 2025

Dec 2025

Mar 2026

Reported quarterly figures (₹ Cr). Latest: revenue ₹1.1K Cr, net profit ₹162 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.

Full financials →

What Bayer CropScience Ltd's management said in earlier quarters

Compare:vs Coromandel International Ltd vs Fertilizers & Chemicals Travancore Ltd vs UPL

🔎 Who's planning the most growth?

Companies ranked by management's own guidance — revenue, margins, capex and order book, from every earnings call in India.

See rankings →

Frequently Asked Questions

What were Bayer CropScience Ltd Q4 FY19 results?

What is Bayer CropScience Ltd share price analysis?

Bayer CropScience Ltd currently shows a neutral. The stock trades at a P/E of 23.2 with a market cap of ₹16,986 Cr. Investors should review the full earnings analysis for detailed insights.

Is Bayer CropScience Ltd planning capital expenditure?

The investor presentation does not explicitly detail any specific capex amounts, capacity expansions, or new plant/projects with their costs, statuses, or timelines.

Keep Bayer CropScience Ltd on your radar — track it to get its next earnings analysis in your feed.

This analysis is AI-generated based on publicly available earnings data and the company's investor presentation. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.